Ｐａｇｅ 824899 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼craniocerebral trau Reorimoms 13/9/26(木) 18:08 ─────────────────────────────────────── ■題名 ： craniocerebral trau ■名前 ： Reorimoms <kicknigopkb@allairmaxsaleoutlet.us> ■日付 ： 13/9/26(木) 18:08 ■Ｗｅｂ ： http://www.coach-outlets-discount.com/ -------------------------------------------------------------------------
| Buried in the オロビアンコ バッグ メンズ ビジネス Dealing that progressively Hollywood sensations are wearing boots from UGG Australia オロビアンコ バッグ ブルーグレー Dealing that progressively Hollywood sensations are wearing boots from UGG Australia オロビアンコ バッグ メンズ Dealing that progressively Hollywood sensations are wearing boots from UGG Australia オロビアンコ レディース ユナイテッドアローズ Generic Drugs Battlefield Generic pharmaceuticals as an market has really favorable demand dynamics. Several secular trends are converging that could advantage オロビアンコ バッグ レディース this market. are aggressively looking for out methods to decrease skyrocketing health care charges. Due to the fact オロビアンコ バッグ メンズ 人気 1960, healthcare spending has expanded from 5% of GDP to over 17% in 2009. Prescription drugs account for about 10% of all healthcare spending, so this is an apparent area to target. Generic versions of branded drugs in general sell for half to onethird from the value. Given this, health care payers have typically オロビアンコ バッグ メンズ 新作 restricted reimbursement to generic versions of specific remedies, raising the demand for them. From 2004 to 2009, generics industry share rose from 56% of prescription dollars to practically http://xn--cckp2a1j7eob1457jm0f.tooth-body.com/ 75%. Among the list of 2010 healthcare bill's key objectives was to raise access to the roughly 15% of Americans with no health insurance. By eliminating insurance coverage denials resulting from existing conditions, preventing the dropping coverage for sick sufferers, and supplying incentives to compact businesses giving coverage, far more consumers will likely be insured and much more individuals might be http://xn--cckp2a2a8irdud5bc.lwvlosangeles.com/ capable to purchase prescriptions. Lastly, there is certainly オロビアンコ 時計 評判 demographics. The amount of Americans over 65 will increase 3% a year over the next ten http://xn--cckp2a1j7eob0556cok1a.tooth-body.com/ years, an further 14 million persons entering Medicare. Naturally, older folks commonly require a lot more healthcare care, like prescription drugs. Put it all together and also the picture is bright for generics. This trend is set to accelerate more than the subsequent few years. six オロビアンコ レディース ユナイテッドアローズ with the major 20 greatest オロビアンコ バッグ メンズ 新作 promoting branded drugs are set to drop patent protection in 2011 and 2012, with two more オロビアンコ バッグ メンズ 人気 drugs that have more than a billion dollars a year in sales expiring in 2012. That's an astounding $43 billion dollars in branded drug sales which will be open to generic competitors. So it would seem to become a slam dunk to advocate generics maker Par Pharmaceuticals (PRX) as an desirable Magic Formula stock. Par generates 90% of its sales from generics, and all of its income. Par features a two pronged tactic. First, it targets smaller sized and much less competitive drugs to create. By undertaking this, the firm can beat its competitors in filing abbreviated new drug applications (ANDAs) with all the FDA, which gives 180 days of marketing and advertising exclusivity right after the branded drug goes off patent. That is substantial within the generics company windfalls from highmargin sales in these 180 days can frequently generate a few "normal years" worth of earnings. This gives Par a slight competitive benefit and also enables them to charge a little much more. On the downside, it frequently calls for Par to spend royalties to the branded maker. Par is not pretty the slam dunk it would seem オロビアンコ バッグ メンズ ボストン to become. The enterprise is just not targeting any from the aforementioned blockbuster drugs there's just a lot of competition http://xn--cckp2a1j7eob5289c317a.tooth-body.com/ for them. And that is among the list of major troubles with this sector. Scale is hugely essential http://xn--cckp2a1j7eob5289c317a.lwvlosangeles.com/ to creating economical gross margins and sustaining the legal talent necessary to succeed in patent challenges. At just $1 billion in sales, Par pales in comparison to Teva (TEVA) ($16 billion), Sandoz (NVS) ($9 billion), or Mylan (MYL) ($5.four billion), to not mention many similar sized competitors. Once exclusivity periods finish, competition normally floods into the marketplace, driving down sales and margins. A good instance オロビアンコ 時計 ブルー of this can be Par's biggest solution: a generic version of AstraZeneca's (AZN) Toprol XL (metroprolol). Early on, competitors was restricted, and then there was no competitors in initially 2 quarters of 2009, driving a 100% sales increase オロビアンコ ベルト 時計 over 2008. Having said that, Watson (WPI) came into the marketplace in late 2009, and because オロビアンコ 時計 レディース then an Indian generics firm has also entered. Pricing and volumes suffered. Inside the justreported initial quarter of 2011, metroprolol sales fell 65% over the prior year! Competition can also result in cheating. In Q1, Par recorded a $190 million charge to settle claims of your business オロビアンコ ベルト 日本製 overinflating the wholesale costs オロビアンコ 時計 ベルト they report to insurers. The alleged scheme is that Par (and competitors) charge much less to pharmacies and report greater promoting prices to insurers. Considering that the insurer is reimbursing the pharmacy at a greater price than they pay for the drugs, it's a good reason オロビアンコ ベルト プレゼント for the pharmacy to choose Par's solution over a competitor's. This can be a difficult provider to worth. It truly is hard to predict the impact of new competitors on current sales, and if Par are going to be able to win exclusivity. The firm reports 12 firsttofile ANDAs, 2 potential firsttomarket opportunities, and plan 5 to 7 new ANDA filings a year over the subsequent few years. Revenues and profitability are very boomandbust. Par also features a branded drug unit named Strativa, but so far this unit has been unprofitable, and likely will remain so for quite a few years. One can find a variety of possibilities for Par, but a median case puts a fair worth http://xn--cckp2a1j7eob1457jm0f.lwvlosangeles.com/ of about $40 around the stock. Because this is a incredibly uncertain calculation, MagicDiligence has a neutral opinion. You will find greater Magic Formula stocks to consider. |